Humasis Co. Ltd. (KOSDAQ:205470)
South Korea · Delayed Price · Currency is KRW 2,650.00
-25.00 (-0.93%)
Jun 11, 2026, 3:30 PM KST
Humasis Revenue
Humasis had revenue of 8.92B KRW in the quarter ending March 31, 2026, with 44.76% growth. This brings the company's revenue in the last twelve months to 32.87B, up 10.65% year-over-year. In the year 2025, Humasis had annual revenue of 30.11B with 18.49% growth.
Revenue (ttm)
32.87B
Revenue Growth
+10.65%
P/S Ratio
1.84
Revenue / Employee
476.41M
Employees
69
Market Cap
60.54B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 30.11B | 4.70B | 18.49% |
| Dec 31, 2024 | 25.41B | 11.59B | 83.79% |
| Dec 31, 2023 | 13.83B | -457.45B | -97.07% |
| Dec 31, 2022 | 471.27B | 149.44B | 46.44% |
| Dec 31, 2021 | 321.83B | 276.11B | 603.96% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4.81T |
| Celltrion | 4.47T |
| Samsung Epis Holdings | 1.51T |
| ALTEOGEN | 203.76B |
| PharmGen Science | 171.66B |
| Yuyu Pharma | 143.52B |
| LabGenomics | 84.19B |
| ORIENT BIO | 59.09B |